Startup profile for General Medicine: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

General Medicine funding, valuation and investors

Consumer healthcare marketplace for comparing and buying medications, labs, telehealth and care services.

Verified company research · funding, investors and latest developments

Keep track of General Medicine

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$120M · October 6, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$120M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b · San Francisco, California, United States

Investors in latest funding

Lead: Andreessen Horowitz

Other: Matrix , VXI Capital , Eli Lilly and Company , Granger Management , BoxGroup

Sources: latest funding · prnewswire.com Last verified: 2026-10-07

Overview

General Medicine operates a nationwide healthcare store in the United States with a catalog spanning medications, labs, telehealth, specialist e-consults and selected in-person services.

Why General Medicine is interesting

General Medicine is trying to package fragmented healthcare purchasing into a consumer-style catalog with upfront pricing both with and without insurance.

Funding history (newest first)

Series B

2026-10-06 $120M
  • Andreessen Horowitz (lead)
  • Matrix (participant)
  • VXI Capital (participant)
  • Eli Lilly and Company (participant)
  • Granger Management (participant)
  • BoxGroup (participant)

Source: Read source · prnewswire.com

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.